Lutetium-177 Prostate Specific Membrane Antigen Therapy in a Patient With Double Malignancy and Single Functioning Kidney: A Case Report

Lutetium-177 labeled with 617 types of Prostate Specific Membrane Antigen ((177)Lu PSMA-617) Radio-ligand Therapy (RLT) is an emerging modality of choice for the treatment of metastatic castration-resistant prostate carcinoma (mCRPC). After it is administered intravenously, it is excreted primarily...

Descripción completa

Detalles Bibliográficos
Autores principales: Naeem, Zikriya, Zahra, Umal Baneen, Numair Younis, Muhammad, Khan, Irfan Ullah, Shahid, Abubaker
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Radiation Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148966/
https://www.ncbi.nlm.nih.gov/pubmed/37131569
http://dx.doi.org/10.7759/cureus.36938

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148966/
https://www.ncbi.nlm.nih.gov/pubmed/37131569
http://dx.doi.org/10.7759/cureus.36938

Ejemplares similares